For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.

TitleTargeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.
Publication TypeJournal Article
Year of Publication2019
AuthorsWang K-J, Wang C, Dai L-H, Yang J, Huang H, Ma X-J, Zhou Z, Yang Z-Y, Xu W-D, Hua M-M, Lu X, Zeng S-X, Wang H-Q, Zhang Z-S, Cheng Y-Q, Liu D, Tian Q-Q, Sun Y-H, Xu C-L
JournalClin Cancer Res
Volume25
Issue3
Pagination1070-1086
Date Published2019 02 01
ISSN1078-0432
KeywordsAdaptor Proteins, Signal Transducing, Animals, Autocrine Communication, Benzimidazoles, Cell Line, Tumor, Cisplatin, Disease Progression, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Humans, Male, Mice, Inbred NOD, Mice, SCID, Neoplastic Stem Cells, Quinolines, Receptors, Platelet-Derived Growth Factor, Transcription Factors, Urinary Bladder Neoplasms, Verteporfin, Xenograft Model Antitumor Assays
Abstract

PURPOSE: Cancer stem-like cells (CSCs) contribute to bladder cancer chemotherapy resistance and progression, but the associated mechanisms have not been elucidated. This study determined whether blocking an autocrine signaling loop in CSCs improves the therapeutic effects of -platinum on bladder cancer.

EXPERIMENTAL DESIGN: The expression of the epithelial marker OV6 and other markers in human bladder cancer specimens was examined by IHC. The CSC properties of magnetic-activated cell sorting (MACS)-isolated OV6 and OV6 bladder cancer cells were examined. Molecular mechanisms were assessed through RNA-Seq, cytokine antibody arrays, co-immunoprecipitation (co-IP), chromatin immunoprecipitation (ChIP) and other assays. An orthotopic bladder cancer mouse model was established to evaluate the effects of a YAP inhibitor (verteporfin) and a PDGFR inhibitor (CP-673451) on the -platinum resistance of OV6 CSCs in bladder cancer.

RESULTS: Upregulated OV6 expression positively associated with disease progression and poor prognosis for bladder cancer patients. Compared with OV6 cells, OV6 bladder cancer cells exhibited strong CSC characteristics, including self-renewal, tumor initiation in NOD/SCID mice, and chemotherapy resistance. YAP, which maintains the stemness of OV6 CSCs, triggered PDGFB transcription by recruiting TEAD1. Autocrine PDGF-BB signaling through its receptor PDGFR stabilized YAP and facilitated YAP nuclear translocation. Furthermore, blocking the YAP/TEAD1/PDGF-BB/PDGFR loop with verteporfin or CP-673451 inhibited the -platinum resistance of OV6 bladder cancer CSCs in an orthotopic bladder cancer model.

CONCLUSIONS: OV6 could be a helpful indicator of disease progression and prognosis for patients with bladder cancer, and targeting the autocrine YAP/TEAD1/PDGF-BB/PDGFR loop might serve as a remedy for -platinum resistance in patients with advanced bladder cancer.

DOI10.1158/1078-0432.CCR-18-0586
Alternate JournalClin Cancer Res
PubMed ID30397177

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587